← AI Health Hub

AI Ethics 1 min read

AI Scribes Facing Strict Medical Device Rules

Dozens of AI transcription tools in clinical practices may actually be unapproved medical devices.

Yusuf Yesil, MD, MIS

Australia’s Therapeutic Goods Administration evaluated 12 digital scribe products and found that eight contained functions meeting the definition of a medical device. Not a single supplier had registered their software as one. Instead, vendors relied on standard disclaimers to bypass strict regulatory oversight.

Bypassing Regulatory Oversight

The gap between software capabilities and regulatory classification is closing fast. Scribes are no longer just transcribing notes. Modern generative AI features routinely draft treatment plans and suggest diagnoses.

Regulators are making it clear that liability disclaimers do not excuse software from medical device laws. If a tool acts like clinical decision support software, it requires formal clearance regardless of its marketing labels.

The Operational Fallout

Adoption is outpacing oversight. Usage of these tools among surveyed general practitioners jumped from 22% in 2024 to 40% by late 2025. Clinics using unapproved software now face significant regulatory liability.

Health systems must immediately audit their digital scribe vendors. If a vendor cannot provide proof of medical device compliance for its analytical features, clinics must restrict the software to basic speech-to-text functionality.

This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment.

Yusuf Yesil, MD, MIS
Yusuf Yesil, MD, MIS

Founder & Medical Doctor at Yesil Science. Clinical Biochemistry Specialist and Health AI researcher focused on clinical decision support, diagnostic AI, and biomedical machine learning.

Follow AI Health Hub